oxidopamine and oxepins

oxidopamine has been researched along with oxepins in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Andringa, G; Cools, AR; Hafmans, TG; Stoof, JC; Unger, W; van Oosten, RV; Veening, J	1
Hengerer, B; Spooren, WP; Waldmeier, PC	1

Other Studies

2 other study(ies) available for oxidopamine and oxepins

Article	Year
Systemic administration of the propargylamine CGP 3466B prevents behavioural and morphological deficits in rats with 6-hydroxydopamine-induced lesions in the substantia nigra. The European journal of neuroscience, 2000, Volume: 12, Issue:8 Topics: Animals; Antibodies; Apoptosis; Behavior, Animal; Body Weight; Denervation; Dopamine; Exploratory Behavior; Gait; Male; Maze Learning; Nerve Degeneration; Neurons; Oxepins; Oxidopamine; Pargyline; Parkinson Disease, Secondary; Propylamines; Rats; Rats, Wistar; Substantia Nigra; Sympatholytics; Tyrosine 3-Monooxygenase	2000
CGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease. Naunyn-Schmiedeberg's archives of pharmacology, 2000, Volume: 362, Issue:6 Topics: 1-Methyl-4-phenylpyridinium; Animals; Antiparkinson Agents; Brain; Cell Culture Techniques; Cell Death; Disease Models, Animal; Dopamine; Female; Liver; Mesencephalon; Mice; Mice, Inbred C57BL; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurons; Oxepins; Oxidopamine; Parkinsonian Disorders; Pregnancy; Rats; Selegiline; Substantia Nigra; Tritium; Tyrosine 3-Monooxygenase	2000

Article

Year

Systemic administration of the propargylamine CGP 3466B prevents behavioural and morphological deficits in rats with 6-hydroxydopamine-induced lesions in the substantia nigra.

The European journal of neuroscience, 2000, Volume: 12, Issue:8

Topics: Animals; Antibodies; Apoptosis; Behavior, Animal; Body Weight; Denervation; Dopamine; Exploratory Behavior; Gait; Male; Maze Learning; Nerve Degeneration; Neurons; Oxepins; Oxidopamine; Pargyline; Parkinson Disease, Secondary; Propylamines; Rats; Rats, Wistar; Substantia Nigra; Sympatholytics; Tyrosine 3-Monooxygenase

2000

CGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease.

Naunyn-Schmiedeberg's archives of pharmacology, 2000, Volume: 362, Issue:6

Topics: 1-Methyl-4-phenylpyridinium; Animals; Antiparkinson Agents; Brain; Cell Culture Techniques; Cell Death; Disease Models, Animal; Dopamine; Female; Liver; Mesencephalon; Mice; Mice, Inbred C57BL; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurons; Oxepins; Oxidopamine; Parkinsonian Disorders; Pregnancy; Rats; Selegiline; Substantia Nigra; Tritium; Tyrosine 3-Monooxygenase

2000